FiteBac Technology

FiteBac Technology FiteBac® is a versatile antimicrobial technology.

Dr. Kirk Kimmerling, CEO and Founder of Fitebac Technologies, was honored to attend the Fall 2023 Longwood Healthcare L...
09/18/2023

Dr. Kirk Kimmerling, CEO and Founder of Fitebac Technologies, was honored to attend the Fall 2023 Longwood Healthcare Leaders conference held September 18-19, 2023. The event provided “BioPharma industry leaders will convene in person at the Joseph B. Martin Conference Center at Harvard Medical School for an off-the-record networking and brainstorming forum focused on accelerating the translation of discoveries into medicines to help patients.”
For more information on FiteBac Technologies: www.fitebactechnology.com
https://www.longwoodhealthcareleaders.com/fall2023

The Longwood Healthcare Leaders meeting, September 18-19, 2023, is centered on Harvard Medical School via webconference with leading biopharma CEOs, heads of R&D, top academic researchers, and healthcare investors.

Explore the chemistry behind FiteBac®TEOS (tetraethyl ortho silicate) is the anchoring unit for SiQAC and other organofu...
08/21/2023

Explore the chemistry behind FiteBac®
TEOS (tetraethyl ortho silicate) is the anchoring unit for SiQAC and other organofunctional trialkoxysilanes (e.g. vinyl, epoxy, isocynate or methacryloxy functionalities)In a mix and match approach, different end functional macro monomers may be synthesized with permanent, non leaching, microbiocidal activities that are independent of the loss of the surface layer, as the activity has been incorporated throughout the product.

This is "FiteBac Platform Chemistry" by VideoHub on Vimeo, the home for high quality videos and the people who love them.

Researchers “ used the K21 drug candidate to evaluate itsanti-inflammatory or inhibitory role against inflammations…Thes...
08/21/2023

Researchers “ used the K21 drug candidate to evaluate its
anti-inflammatory or inhibitory role against inflammations…These novel findings established the inflammatory-response-induced LPS treatment and the inhibitory effect of the K21 drug on LPS-induced inflammation.” Publication July 13, 2023.
Additional Info: www.fitebactechnology.com

NF-κB signaling has broad effects on cell survival, tissue growth, and proliferation activities. It controls many genes that are involved in inflammation and thus is a key player in many inflammatory diseases. The elevation of NF-κB activators is associated with elevated mortality, especially in c...

We’re Presenting at BioFuture!FiteBac Technologies is presenting at BioFuture™. See our live presentation during the in-...
08/21/2023

We’re Presenting at BioFuture!
FiteBac Technologies is presenting at BioFuture™. See our live presentation during the in-person event Oct. 4-6 in NYC at the Lotte New York Palace. Virtual attendees can view our recorded presentation online. Be sure to connect with us after you watch our presentation!
Additional Info: www.fiteBactechnology.com

Address

Marietta, GA

Alerts

Be the first to know and let us send you an email when FiteBac Technology posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to FiteBac Technology:

Share